Experimental drug combo aims to shrink inoperable liver tumors
NCT ID NCT05864105
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This phase II trial is testing whether a new biologic drug called PM8002, when combined with standard chemotherapy (FOLFOX), can shrink tumors in people with advanced liver cancer that cannot be removed by surgery. The study enrolls about 35 adults with inoperable hepatocellular carcinoma who have not received prior systemic therapy. Researchers will measure how many patients experience tumor shrinkage or disappearance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PM8002 (a biologic drug) plus FOLFOX chemotherapy (oxaliplatin, leucovorin, 5-fluorouracil)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with inoperable liver cancer, potentially shrinking tumors and improving outcomes.
- What could go wrong
- This is an early phase II study with only 35 participants, so results may not apply broadly. The combination may cause significant side effects, and the drug may not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Cancer Hospital of The University of Chinese Academy of Sciences
Hangzhou, Zhejiang, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Jinhua Municipal Centeral Hospital Medical Group
Jinhua, Zhejiang, China
-
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
-
The First Hospital of Jilin University
Changchun, Jilin, China
-
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer vaccine prime the body to better fight liver tumors?
- Training the immune system to hunt down leftover liver cancer cells
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- Can a tumor-zapping procedure also wake up the immune system?
- A machine that keeps donor livers alive outside the body — could it transform transplantation?